Author:
Li Fengying,Xie Xinyou,Ren Xiaobin,Zhang Jun
Funder
National Natural Science Foundation of China
Zhejiang Provincial Natural Science Foundation
Key Program of the Science Technology Department in Zhejiang Province
Zhejiang Province Medicine and Health Science and Technology Plan Project
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference50 articles.
1. Zamble DB, Mu D, Reardon JT, Sancar A, Lippard SJ (1996) Repair of cisplatin–DNA adducts by the mammalian excision nuclease. Biochemistry 35(31):10004–10013
2. Reardon JT, Vaisman A, Chaney SG, Sancar A (1999) Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 59(16):3968–3971
3. Kartalou M, Essigmann JM (2001) Mechanisms of resistance to cisplatin. Mutat Res 478(1–2):23–43
4. Vilmar A, Sorensen JB (2009) Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer 64(2):131–139
5. van Duin M, Koken MH, van den Tol J, ten Dijke P, Odijk H, Westerveld A, Bootsma D, Hoeijmakers JH (1987) Genomic characterization of the human DNA excision repair gene ERCC-1. Nucleic Acids Res 15(22):9195–9213
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献